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well-being. Exenatide: no PRO US/EU label claims sought. Lorcaserin: PRO-data 
supported US-approval (no label-claim). PRO-data supported MA for the UK and 
US. Key findings from payer interviews (n= 6 EU/n= 4 US) revealed that health-
care-system differences influence payer-preferences for PRO-type (e.g., generic/
disease-specific), influenced primarily by need for cost-effectiveness model. All 
payers stated that PRO-data provide unique perspective on condition/treatment 
but considered reimbursement difficult to influence; although stated that PRO-data 
can positively impact prescribing/MA. Payers reported that in EU, PROs are part of 
the clinical-evidence considered by HTA reviewing committees. Utility data derived 
from generic instruments are essential for key EU-markets (excluding Germany). 
US health plans are interested in PRO measures that are tied to “actionable” end-
points (e.g., adherence/persistence, tolerability, reduction in costs or resource 
utilisation). CONCLUSIONS: Key drivers for a successful PRO strategy include the 
development of robust PRO and communication strategy tailored to the needs/
requirements of the end-users (regulators, HTA and MA). Sponsors must continue 
to bring data based on robust PROs to regulators, HTA and MA and thus bringing 
the patient, the most affected stakeholder, to the forefront in decision making.
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OBJECTIVES: To assess current status of disease control and treatment satisfaction 
in patients with acromegaly in the United States. METHODS: A web-based cross-
sectional survey was conducted from August –October, 2014. Acromegaly patient-
reported information on treatment satisfaction and preference, symptom control, 
and comorbidities were collected and analyzed descriptively. RESULTS: A total of 
106 patients completed the survey (mean age: 46 years, female: 76%). Patients had 
a 5-year diagnosis delay after symptom onset. Most patients (91%) had undergone 
surgery. Of 68 patients on pharmaceutical therapy: 79% were on somatostatin ana-
logs, 22% on dopamine agonists and 13% on GH-receptor antagonists. Almost half 
of the patients (47/106) presented with 5 or more comorbidities (depression 57%, 
hypertension 43%, musculoskeletal and connective tissue abnormalities 42%, sleep 
apnea 37%, cardiac and cardiovascular diseases 32%, and diabetes 32%). There were 
96 (91%) patients reporting acromegaly-related symptoms (e.g. headache, excess 
sweating, and joint pain). As compared with the low-symptom group 0-3 (n= 41), the 
high-symptom group with 4+ symptoms (n= 65) were more likely to have depression 
(OR= 2.33, 95% CI, 1.05-5.19) and cardiovascular disease (OR= 5.80, 95% CI, 2.02-16.67). 
Among patients on injectables (n= 61), 61% had worse symptoms toward the end of 
injection cycle, and 38% requested medical intervention (i.e. additional daily injec-
tion, unscheduled injection, or oral medicines). 84% of patients reported that the 
symptoms interfered with daily life and work; 85% felt frustrated. The treatment 
satisfaction rate was 56%; 33% didn’t like having injections. The top patients’ prefer-
ences for new acromegaly treatments were to avoid injections (e.g., oral formula-
tion) (85%), improve disease management such as patients’ support (62%), and to 
provide better patient education (57%). CONCLUSIONS: More than 40% of patients 
were not satisfied with their current treatment for acromegaly. Patients want better 
therapy (e.g., oral drugs), improved disease management, and education programs.
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OBJECTIVES: The present study aimed to assess the dietary knowledge, myths and 
misconceptions among diabetic patients in Quetta, Pakistan. METHODS: The study 
was conducted as a cross sectional, questionnaire based study covering diabetic 
patients in public and private hospitals and diabetic clinics of Quetta city, Pakistan. 
A self-administered questionnaire was used evaluate the dietary knowledge, myths 
and misconception about diabetes. The questionnaire constructed with a total of 20 
(10 questions each for dietary knowledge, myths and misconception). Continuous 
variables were expressed as mean ± SD, and categorical variables are represented 
in frequency and percentage. RESULTS: A total of 400 questionnaires were dis-
tributed out of which 320 were received and included in the study. The study is 
dominated with male respondents (59.7%, n= 191), with majority (37.2%, n= 119) 
categorised in age group between 25-34 years and married (78.4%, n= 251) with 
education level as S.S.C (matriculation) (39.1%, n= 125). The mean dietary knowledge 
score was 4.81± 1.2 and myths and misconception score was 3.32± 1.8 both catego-
rised as poor. CONCLUSIONS: The study concluded that diabetes patients has poor 
knowledge regarding dietary knowledge and has high prevalence of dietary myths 
and misconceptions. Patients should be educated for proper dietary changes to be 
adopted for better disease control.
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OBJECTIVES: An important characteristic of successful healthcare and patient 
participation in clinical trials is strong communication between patients and 
their providers. Using e-clinical technology can be one mechanism for achieving 
this goal. We propose that the optimal implementation considers patient prefer-
ence and ease of use, and that incorporating e-clinical technology can lead to 
increased patient compliance and ultimately improved clinical care. METHODS: 
We surveyed 105 patients in the U.S. with diabetes; questions focused on mobile 
technology use, perceptions, and preferences. RESULTS: Patients were diverse in 
tion value= 0.75, and negative prediction value= 0.62. Temporal validation showed 
decrease in the sensitivity (0.69) and specificity (0.60) statistics. CONCLUSIONS: 
RxAPT shows promise as an effective tool to identify patients who are likely to 
become non-adherent to diabetes medications in the follow-up year. Further valida-
tion is needed before the tool can be implemented in a real world setting.
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OBJECTIVES: This study describes the relationship between health-related quality of 
life (HR-QoL) assessed using the SF-36v2 and adherence as measured by the Morisky 
Medication Adherence Scale (4-item MMAS-4 , 8-item MMAS-8, and a 4-item scoring 
of the MMAS-8) among US adults with type 2 diabetes (T2D). METHODS: Data were 
taken from the 2011 and 2012 US National Health and Wellness Survey (NHWS). The 
NHWS is a large cross-sectional survey representative of the total adult population 
in several major markets; N~75,000/year in the US. A total of 13,007 respondents 
self-reported physician diagnosis of T2D and were administered MMAS-4 in 2011 
or MMAS-8 in 2012. The relationship between SF-36v2 measures and adherence 
was described for the two adherence scales and also a scoring of the MMAS-8 that 
uses only the 4 items best matched to the questions in the MMAS-4. RESULTS: In 
T2D patients, MMAS-4 resulted in a greater percentage of respondents classified as 
having high adherence than MMAS-8 (64% vs. 44%) and a lower percentage of low 
adherence (3% vs. 19%), while medium adherence was fairly similar (33% vs. 37%). 
The 4-item scoring of the MMAS-8 was more similar to MMAS-4 (79% high, 15% 
medium, 6% low). In OLS regressions controlling for sociodemographic characteris-
tics (e.g. age, gender, comorbidities, education, income), all measures of adherence 
were significant predictors of HR-QoL, with two main differences: R-squared values 
were slightly lower for regressions including MMAS-4 adherence and MMAS-4 was 
not predictive of Physical Component Summary (PCS) scores. CONCLUSIONS: All 
three adherence scores are significantly correlated with the Mental Component 
Summary and SF-6D health utility scores of the SF-36v2, MMAS-4 fails to correlate 
with PCS. The variation in proportion of patients classified as highly adherent across 
scales also suggests pooling such classifications across data using different versions 
of the MMAS is not advisable, at least among T2D patients.
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OBJECTIVES: Type 2 diabetes (T2D) is a chronic condition with well-described long-
term cardiovascular consequences and other co-morbidities. This study investigated 
the short-term impact of poor glycemic control on T2D patients’ daily lives to help 
define the health states for inclusion in a time trade off study (TTO). METHODS: 
Adult respondents in Denmark receiving medical treatment for T2D, and knowing 
their HbA1c level, completed an online survey based on results from prior telephone 
interviews with patients to identify perceptions on weight, simplicity of insulin 
regimen and aspects of well-being affected by change in HbA1c. Questions covered 
demographics and insulin regimen, most recent HbA1c and change from previous 
HbA1c, how often they experience certain physical and psychological symptoms 
(1–5 with 1= never and 5= always), if respondents wanted to reduce HbA1c, and the 
extent to which key criteria were felt to prevent reducing HbA1c (1–5 with 1= full 
extent and 5= not at all). RESULTS: 268 respondents (72% men, mean age 66.5 years) 
completed the survey. Average change in HbA1c was 2.0%. Frequency of excessive 
thirst reduced significantly with a > 1% drop in HbA1c and the effect increased with 
further decreasing HbA1c. Similar results were found for frequency of urination. 
Fatigue and lack of energy also improved with decreasing HbA1c. Almost 100% 
of respondents with HbA1c ≥ 9% wished to reduce their HbA1c, compared to 61% 
with HbA1c < 7%. Answering “to what extent does the following explain why your 
HBA1c is not lower?”, the highest response was ‘to avoid gaining weight’, lowest 
response was ‘forgetting to take medication’. CONCLUSIONS: Symptoms improve 
with reduced HbA1c, and the majority of respondents wish to lower their HbA1c. 
Changes in HbA1c are perceived to have a major impact on daily lives; however, 
there are still a variety of barriers preventing people with T2D from lowering their 
HbA1c.
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OBJECTIVES: To identify key drivers for the successful integration of patient-
reported outcomes (PROs) in clinical programs designed to support regulatory label 
claims, health technology assessment (HTA) and market access (MA) in diabetes 
and obesity. METHODS: Reviews of published literature, regulatory, HTA and third-
party websites were conducted to elicit key components of PRO strategies employed 
for two case examples: exenatide (diabetes) and lorcaserin (obesity). Qualitative 
one-on-one interviews were also conducted with payer decision-makers in key 
European (EU) and United States (US) markets to determine their perceptions of 
successful PROs strategies. RESULTS: Although there is an FDA draft guidance on 
PROs to support labeling claims, no disease-specific guidance on PRO-endpoints 
for obesity/diabetes are issued by FDA or EMA. Registration-trials included assess-
ments of; symptoms/health-related-quality-of-life/depression/psychological-
